• Fortress Biotech repaid the remaining USD 15 million outstanding under its USD 50 million senior secured credit facility on Sept. 30, 2026.
• Payment included about USD 435,000 of accrued interest, a USD 150,000 prepayment fee, and other closing costs.
• Debt under the Oaktree Agreement was satisfied in full, triggering release of all related liens and termination of the agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-112845), on October 01, 2026, and is solely responsible for the information contained therein.